According to the company, CytoTool’s active ingredient DPOLC has shown positive results in test series for its effectiveness on influenza viruses. As before against the COVID-19 pathogen SARS-COV-2, DPOLC has also shown a virus-killing effect on influenza viruses, CytoTools said in a statement on Monday. Depending on the dose, efficiencies of up to more than 90 percent have been determined.
However, the tests are still in the early stages: So far there have been cell culture experiments with infuenzaviruses and the active ingredient that is already approved in India for the treatment of diabetic foot.
“The second wave of COVID-19 has understandably led to a considerable amount of extra time also for our cooperation partners,” explains Mark-André Freyberg, CEO of CytoTools. “The preliminary results now available reflect what was to be expected according to our internal test series: DPOCL is highly virucidal. When used as an inhalation component, it opens up fundamentally new approaches in the treatment of influenza virus infections, ”says the manager.
Beo CytoTools is now hoping for new partners for the further development of DPOLC: “Effective therapies against virus flu infections are rare and generally have noticeable side effects. For us this significantly increases the chances of bringing our talks about a project partnership to a successful conclusion in the first quarter ”, says Dirk Kaiser, Board Member for Research and Development at CytoTools AG.
Livestream on December 14th, 2020 from 6 p.m .:
With Hans-Werner Sinn, former President of the Ifo Institute: Corona and the miraculous increase in money in Europe
– Here is the stream! –